Core Viewpoint - The return of Chen Yong, the actual controller and chairman of Yong'an Pharmaceutical, is expected to stabilize the company's management and potentially improve its performance amid ongoing challenges in the taurine market and new business development opportunities [1][6]. Group 1: Management Changes - Chen Yong has resumed his duties after the lifting of the detention measures, allowing him to manage the company normally [1]. - The transition of responsibilities to Chen Zidi has been completed, ensuring continuity in leadership during Chen Yong's absence [1][2]. Group 2: Financial Performance - Yong'an Pharmaceutical has experienced a decline in revenue for three consecutive years, with revenues of 1.462 billion, 973 million, and 839 million yuan from 2022 to 2024, representing year-on-year decreases of 6.58%, 33.48%, and 13.78% respectively [3]. - The core business of taurine generated 635 million yuan in revenue in 2024, accounting for 75.67% of total revenue, but saw a year-on-year decline of 4.14% despite a 16.32% increase in sales volume due to falling prices [3]. Group 3: Operational Challenges - The company's epoxy ethane and Qian'an hydrogen energy facilities were largely idle, resulting in a loss of 17.588 million yuan, which constituted 28.47% of net profit attributable to shareholders [4]. - The production of taurine has been impacted by increased costs due to the need to purchase raw materials, further squeezing profit margins [4]. Group 4: New Business Development - Yong'an Pharmaceutical has initiated a new business line in creatine, which is still in its early stages and unlikely to significantly boost performance in the short term [5]. - The subsidiary Ling'an Technology reported a revenue of 45.7128 million yuan in the first half of the year, a 53.93% increase year-on-year, but also faced a net loss of 6.6258 million yuan, indicating challenges in scaling the new product line [5][6].